Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline Review, H2 2016

GET SAMPLE REPORT @ Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline Review, H2 2016

Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline Review, H2 2016

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline Review, H2 2016, provides an overview of the Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) pipeline landscape.

Relapsing-remitting multiple sclerosis (RRMS) is the most common form of multiple sclerosis (MS). In RRMS, there are clear episodes of inflammatory activity (relapses). During a period of acute inflammation, old symptoms may worsen and new symptoms may appear. A relapse is when active inflammation, and the resulting symptoms, last more than 24 hours. Symptoms include tingling or numbness, double vision, fatigue, urinary urgency and weakness. Treatment includes corticosteroids and immunoglobulin therapy.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 5, 18, 1, 6 and 1 respectively for Similarly, the Universities portfolio in Phase II and Phase I stages comprises 1 and 1 molecules, respectively for Relapsing Remitting Multiple Sclerosis (RRMS).

Relapsing Remitting Multiple Sclerosis (RRMS) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

ACCESS REPORT @ Relapsing Remitting Multiple Sclerosis (RRMS) – Pipeline Review, H2 2016

Scope

CONTINUE READING